Iev407

Phase 1

Novartis

Iev407 is one of 4 therapeutic programs targeting Advanced HR+/HER2- Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced HR+/HER2- Breast CancerRecruiting

Advanced HR+/HER2- Breast CancerPhase 1

Recruiting

Competition

Competitive Landscape

5 competitors in Advanced HR+/HER2- Breast Cancer

#DrugCompanyPhaseTrials

Femara

Novartis

Phase 1

3 2

Faslodex

FFresenius Kabi USA, LLC

Phase 1

4 3

Kisqali

Novartis

Preclinical

1 4

Iev407

Novartis

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2032

Phase 1Recruiting

Advanced HR+/HER2- Breast Cancer

NCT07604571

Clinical

Trials by Indication[1]

Advanced HR+/HER2- Breast Cancer1 trial

An Open-label, Multi-center, Phase I/Ib Study of IEV407 as a Single Agent and in Combination With Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2- Negative Breast Cancer

Recruiting· Novartis logo

Novartis·Phase 1·NCT07604571·194 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Iev407. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Iev407. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Novartis

Iev407

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2032

Trials by Indication[1]

Advanced HR+/HER2- Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News